Massive dilution risk from the ELOC and potential Series H conversion. Monitor for VWAP purchase notices and shareholder vote on the Series H amendment. The 10% discount pricing will pressure the stock price. Consider short-term bearish bias given the extreme overhang.
Price Chart
Executive Summary
ENvue Medical entered into a $50M committed equity facility (ELOC) with an institutional investor, selling common stock at a 10% discount to VWAP. The company also amended its Series H Preferred Stock purchase agreement to allow up to $59M in additional convertible preferred, subject to shareholder approval. With a $4M market cap and facing Nasdaq delisting, this represents extreme dilution risk.
Key Facts
- Committed equity facility of up to $50M at 90% of lowest 3-day VWAP
- Company market cap is ~$4M, making the facility ~12.5x current market cap
- 50M common shares reserved for issuance under the facility
- Exchange cap of 1,858,403 shares (19.99% of outstanding) unless shareholder approval obtained
- 40% of net proceeds must be used to redeem Series X Preferred Stock
- Series H Preferred amendment increases potential additional investment rights to $59M stated value ($53.1M subscription amount), subject to shareholder approval
- S-3 shelf filed 2 days prior for up to $50M, directly supporting this facility
Financial Impact
Potential dilution of up to 50M shares (multiple times current float) at a 10% discount to market; $50M facility is 12.5x current market cap
Risk Factors
- Extreme dilution from equity line draws at a 10% discount
- Nasdaq delisting risk (sub-$1 bid price) could accelerate draws
- Series H preferred conversion adds further dilution if shareholder approval obtained
- 40% of proceeds earmarked for Series X redemption, limiting working capital benefit
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-037254 |
| Exhibit: ex10-2.htm | 0001493152-26-037254 |
| Document: form8-k.htm | 0001493152-26-037254 |
| Document: 0001493152-26-037254-index-headers.html | 0001493152-26-037254 |
| Document: 0001493152-26-037254-index.html | 0001493152-26-037254 |
| Document: 0001493152-26-037254.txt | 0001493152-26-037254 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | 8-K | $0.4900 | awaiting T+20 | — | $0.2501 (+48.96%) |
Sep 4, 2026 7w ago | EFFECT | $4.03 $1.03 | ▲ +74.44% | ▲ +75.04% | $0.2501 (+93.79%) |
Aug 31, 2026 8w ago | 8-K | $4.31 | awaiting T+20 | — | $0.2501 (−94.20%) |
Aug 12, 2026 10w ago | 8-K | $4.90 $3.57 | ▲ +27.08% | ▲ +25.19% | $0.2501 (+94.89%) |
Aug 10, 2026 11w ago | S-3 | $0.3982 $0.3033 | ▲ +23.82% | ▲ +22.76% | $0.2501 (+37.19%) |
Jul 10, 2026 15w ago | 8-K | $0.4578 $0.4140 | ▲ +9.57% | ▲ +12.75% | $0.2501 (+45.37%) |
Jun 3, 2026 20w ago | Press Release | $0.8600 $0.5200 | ▼ −39.53% | ▼ −38.53% | $0.2501 (−70.92%) |
May 29, 2026 21w ago | EFFECT | $0.9020 $0.5400 | ▲ +40.13% | ▲ +38.34% | $0.2501 (+72.27%) |
May 18, 2026 23w ago | S-3 | $0.9300 $0.7262 | ▲ +21.91% | ▲ +22.90% | $0.2501 (+73.11%) |
May 12, 2026 23w ago | Press Release | $1.24 $0.8530 | ▼ −31.21% | ▼ −29.48% | $0.2501 (−79.83%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers